Senior insider sale
Chief Scientific Officer at NURIX THERAPEUTICS, INC. — senior position signals high conviction
$203.3K
9.51K shares
What this filing means
HANSEN GWENN plans to sell 9.51K shares of NURIX THERAPEUTICS, INC. valued at approximately $203.3K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 8/4/2026ACC: 0001950047-26-007639
Officer· Chief Scientific Officer
Since Jul 2020
9.51K
Shares to sell
$203.3K
Approx. market value
4.11K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months1
Restricted Stock Units
N/A
7/30/2026
4.11KTotal acquired4.11K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
7/30/2026 | Restricted Stock Units N/A | 4.11K | — |
| Total | 4.11K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
5.39K
Market value
$107.9K
6/25/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
4.11K
Market value
$95.5K
8/4/2026
Total
Units
9.51K
Value
$203.3K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
6/25/2026 | 5.39K | $107.9K | — | Completed |
| Planned — Approximate Date | ||||
8/4/2026 | 4.11K | $95.5K | NASDAQ | Planned |
| Total | 9.51K | $203.3K | ||